Tanaz A. Kermani, MD
Accepting new patients

Tanaz A. Kermani, MD

  • Rheumatology
Average rating: 5.0
 
Santa Monica Rheumatology | 2020 Santa Monica Boulevard, Suite 540, Santa Monica, CA 90404
310-582-6350
Request an Appointment

About

Dr. Tanaz Kermani is the Founder and Director of the multi-disciplinary Vasculitis Program(Link opens in new window) at UCLA. She grew up in Mumbai and moved to the United States in 1996 to pursue higher education. She completed her training in Internal Medicine and Rheumatology at the Mayo Clinic in Minnesota. She did additional training in vasculitis at the Mayo Clinic, as part of a prestigious Vasculitis Clinical Research Consortium fellowship. She joined the UCLA Health's Division of Rheumatology in 2012.

Dr. Kermani sees patients with all rheumatological diagnoses but has a special interest and expertise in vasculitis. She is internationally recognized for her clinical and research expertise in vasculitis. She is an active member of the vasculitis research community, with multiple ongoing national and international collaborations with vasculitis patient advocates and medical experts. She has numerous publications.

Dr. Kermani is a clinician at heart and enjoys patient care. She is invested in the well-being of her patients. Her approach is to listen to her patients, elicit their concerns, preferences and values and incorporate these when discussing best options for their care.

Other Videos

Podcasts

Languages

English

Education

Medical Board Certifications

Rheumatology, American Board of Internal Medicine, 2009
Internal Medicine, American Board of Internal Medicine, 2007

Fellowship

Rheumatology, Mayo Clinic College of Medicine and Science, 2010

Residency

Internal Medicine, Mayo Clinic College of Medicine and Science, 2007

Internship

Internal Medicine, Mayo Clinic College of Medicine and Science, 2005

Degree

MD, New York Medical College, 2004

Recognitions

Locations

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Medical Services

Vasculitis Care

Research

Interests

  • Giant Cell Arteritis
  • Polymyalgia Rheumatica
  • Takayasu Arteritis
  • Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome

Publications

Select publications below. For a complete list, link to Dr. Kermani's PubMed publications(Link is external) (Link opens in new window)

Large-vessel manifestations of giant cell arteritis

  1. Kermani TA, Diab S, Sreih A, Cuthbertson D, Borchin R, Carette S, Forbess LJ, Hoffman GS, Koening CL, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Spiera RF, Warrington KJ, Ytterberg SR, Langford CA, Khalidi NA, Merkel PA. Arterial Lesions in Giant Cell Arteritis: A Longitudinal Study. Seminars in Arthritis and Rheumatology.  2019;48(4):707-713.
  2. Muratore F, Kermani TA, Crowson CS, Koster MJ, Matteson EL, Salvarani C, Warrington KJ. Large vessel dilatation in giant cell arteritis: a different subset of disease? Arthritis Care Res (Hoboken). 2018;70:1406-1411. PMID: 29266882.
  3. Kermani TA, Warrington K, Crowson C, Hunder G, Ytterberg S, Gabriel S and Matteson E. Predictors of dissection in aortic aneurysms from giant cell arteritis: A population-based study of predictors. Journal of Clinical Rheumatology. 2016;22(4):184-7.
  4. Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, Warrington KJ. Large-Vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 2015;54:463-70.
  5. Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ. Extra-cranial giant cell arteritis and Takayasu arteritis – How similar are they? Seminars Arthritis Rheum. 2015;44:724-8.
  6. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL. Large-Vessel Involvement in Giant Cell Arteritis: A Population-Based Cohort Study of the Incidence-Trends and Prognosis. Annals of the Rheumatic Diseases, December 2013;72:1989-1994.


Outcome measures in large-vessel vasculitis

  1. Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman G, Khalidi N, Koening C, Langford C, McAlear C, Monach P, Moreland LW, Pagnoux C, Seo P, Warrington K, Ytterberg S, Merkel P. Evaluation of Damage in Giant Cell Arteritis. Rheumatology (Oxford). 2018;57:322-328.
  2. Aydin SZ, Robson JC, Sreih AG, Hill C, Alibaz-Oner F, Mackie S, Beard S, Gul A, Hatemi G, Kermani TA, Mahr A, Meara A, Milman N, Shea B, Tomasson G, Tugwell P, Direskeneli H, Merkel PA. Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. J Rheumtol. 2019.
  3. Sreih A, Alibaz-Oner F, Kermani TA, Aydin SZ,Cronholm, Peter, Davis T, Easley E, Gül A, Mahr A, McAlear C, Milman N, Robson J, Tomasson G, Direskeneli H, Merkel PA. Development of a Core Set of Outcome Measures for Large-Vessel Vasculitis: Report from OMERACT 2016. J Rheumatol. 2017;44:1933-1937.
  4. Kermani TA, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Lanford CA, McKinnon-Maksimowicz K, McAlear CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Merkel PA, Matteson EL. The Birmingham Vasculitis Activity Score as a measure of disease activity in giant cell arteritis. J Rheumatol. 2016;43(6);1078-84.
  5. Kermani TA, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Lanford CA, McKinnon-Maksimowicz K, McAlear CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Merkel PA, Matteson EL. The Birmingham Vasculitis Activity Score as a measure of disease activity in giant cell arteritis. J Rheumatol. 2016;43(6);1078-84.
    PMID:27036388.
  6. Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, McKinnon-Maksimowicz K, Monach PA, Seo P, Merkel PA, Ytterberg SR. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal, cohort study. J Rheumatol. 2015;42(7):1213-7.


Management guidelines

  1. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1-e23.
  2. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan
    EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020;59(3):487-494.


Reviews

  1. Maningding, E and Kermani TA. Mimics of Vasculitis. Rheumatology (Oxford). 2021;60:34-47. PMID: 33167039
  2. Kermani TA. Takayasu arteritis and giant cell arteritis: Are they a spectrum of the same disease. International Journal of Rheumatic Diseases. 2019;22(suppl 1):41-48.
  3. Unizony S and Kermani TA. IL-6 blockade and its Therapeutic Success in Giant Cell Arteritis. Journal of NeuroOphthalmology. 2018;38:551-560.
  4. Kermani TA and Warrington KJ. Prognosis and monitoring of giant cell arteritis and associated complications. Expert Review of Clinical Immunology. 2018;14:379-388.
  5. Kermani TA, Dasgupta B. Emerging therapies in Large-Vessel Vasculitis. Rheumatology (Oxford). 2018;57:1513-1524.
  6. Kermani TA, Warrington KJ. Polymyalgia rheumatica. The Lancet. 2013;5:381:63-72.

Insurance

  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • L.A. Care
  • Medicare Advantage
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • TRICARE
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.

Recognitions

  • Super Doctors® Southern California, 2023, 2024
  • Top Doctors, Los Angeles Magazine, 2022
  • Top Doctors, Los Angeles Magazine, 2019-2021
  • Fellow of the American College of Physicians (FACP), 2014
  • Vasculitis Clinical Research Consortium Fellowship, January 2010 to December 2011
  • The Philip Showalter Hench Award for Excellence in Rheumatology, May, 2010

Links

Reviews

Overall Rating:
5.0
131 total ratings | 15 reviews
5.0
January 29, 2025
Very attentive to the patient. Very well organized office and staff.
5.0
January 8, 2025
Dr Kermani has literally saved my life and help keep me going the past two years despite enormous obstacles I feel so cared for and really appreciate it
5.0
January 6, 2025
She is managing my case with attention and utmost consideration. It’s difficult and rare condition with a lot of potential refractions. Since Doctor took over my case ALL of my symptoms are under control
5.0
January 3, 2025
Dr Kermani takes the time to listen to her patients and figure out where their pain is located. I got bilateral knee injections in her office today and she made the experience a pleasant one. She is the best rheumatologist ucla has on staff !
5.0
January 3, 2025
Very helpful
Load More